Oncology - Hematology: Recent Episodes
ReachMD
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Steven Maron, MD, MSc
Given the recent identification of actionable biomarkers like PD-L1 and MSI-H,1-3 it’s important to test patients with gastroesophageal cancer for these biomarkers as they may provide insights into options for a patient’s treatment plan.4,5 To learn more about how we can detect biomarkers and other key considerations for biomarker screening in gastroesophageal cancer, Dr. Charles Turck speaks with Dr. Steven Maron, a gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center in New York.
References:
- The Cancer Genome Atlas Network. Nature. 2014;513:202-209.
- Fontana E, et al. Ther Adv Med Oncol. 2016;8:113-125.
- Yang B, et al. J Exp Clin Cancer Res. 2019;38:283.
- American Cancer Society. https://www.fightcancer.org/sites/default/files/Improving%20Access%20to%20Biomarker%20Testing_FINAL.pdf. Accessed July 20, 2024.
- Catenacci DVT, et al. Future Oncol. 2019;15:2073-2082.
©2024 Amgen Inc. All rights reserved. USA-OCF-82400 9/24
Host: Jennifer Caudle, DO
Guest: Samuel R. Wilson, MD
Sickle cell disease is among the most common inherited conditions globally, affecting more than seven million individuals worldwide.1-3 Given its prevalence, it is important to understand all of the complexities surrounding this disease. Joining Dr. Jennifer Caudle to discuss the pathophysiology, clinical presentation, burden, and unmet needs of sickle cell disease is Dr. Samuel R. Wilson, Assistant Professor of Medicine in the Division of Hematology at the University of North Carolina School of Medicine.
References:
- Sedrak A, Kondamudi NP. Sickle cell disease. StatPearls Publishing; 2023. Updated August 12, 2023. Accessed April 16, 2024. https://www.ncbi.nlm.nih.gov/books/NBK482384/.
- Thomson AM, McHugh TA, Oron AP, et al. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol. 2023;10(8):e585-e599. doi:10.1016/S2352-3026(23)00118-7.
- CDC. Data & statistics on sickle cell disease. Centers for Disease Control and Prevention. Published May 2, 2022. Accessed April 16, 2024. https://www.cdc.gov/ncbddd/sicklecell/data.html/.
Agios Pharmaceuticals, Inc. © 2024
All right reserved.
SCD-US-0095 / June 2024
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jessie Hsieh, MD
Guest: David Isaacson, MD
About 70 percent of all cancer-related deaths are associated with cancers that don't have recommended USPSTF screening modalities.1 But the good news is that adding multicancer early detection (MCED) testing to usual care screenings could help address this gap and potentially improve outcomes by screening for more cancer types. Joining Dr. Charles Turck to share their experiences with MCED testing and a real-world patient case are Drs. Jesse Hsieh and David Isaacson. Dr. Hsieh is the Chairman of the Board of Beacon Health System in Indiana, and Dr. Isaacson is an Assistant Professor of Otolaryngology at the Indiana University School of Medicine.
Reference:
- Estimated deaths per year in 2022 from American Cancer Society Cancer Facts and Figures 2022. Available at:
http://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/cancer-facts-and-figures-2022.pdf. Data on file GA-2021-0065
Guest: Lori J. Wirth, MD
Head and neck cancers are the seventh most common cancers globally and are increasing in prevalence.1,2 To dive further into the intricacies of this early-stage cancer, join Dr. Lori Wirth, Medical Oncologist in the Head and Neck Oncology Program at Massachusetts General Hospital in Boston.
References:
- Gormley M, et al. Br Dent J. 2022;233(9):780-786.
- Barsouk A, et al. Med Sci (Basel). 2023;11(2):42.
©2024 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved.
EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada.
US-NONO-00581 05/2024
Host: Jennifer Caudle, DO
Guest: Joyce O'Shaughnessy, MD
The results from the phase III EMERALD trial led to the approval of ORSERDU® (elacestrant) as the first oral selective estrogen receptor degrader for ER-positive/HER2-negative metastatic breast cancer patients with ESR1 mutations after disease progression following at least one line of endocrine therapy.1 But given the results from prior analyses, clinicians wanted to better understand the data for elacestrant in subgroups of patients with key clinical or biomarker characteristics, and so a post hoc analysis of elacestrant in these subgroups who typically have a poorer prognosis was conducted. Explore the EMERALD trial and the key outcomes from this subgroup analysis with Dr. Jennifer Caudle and medical oncologist Dr. Joyce O'Shaughnessy.
Guest: Adam Narloch
Guest: Michelle Hermiston, MD, PhD
Adam Narloch speaks with Dr Michelle Hermiston to discuss the history of hemophagocytic lymphohistiocytosis (HLH) and advances in understanding this rare disease. Dr Hermiston is a pediatric hematologist-oncologist, a bone marrow transplant specialist, and the Director of the Pediatric Immunotherapy Program at UCSF Benioff Children’s Hospital. Join us as we start our journey into the world of HLH!
© 2024 Sobi, Inc. All Rights Reserved. NP-34329 04/24
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jamie Koprivnikar, MD
Patients with lower-risk myelodysplastic syndromes (MDS) lack treatment options, specifically in treating anemia. However, the FDA approval of Reblozyl (luspatercept-aamt) as a first-line therapy for treating anemia in ESA-naïve patients with lower-risk MDS presents an option for this patient population. Tune in to learn more about evaluating patients with MDS, the potential of Reblozyl, and where it fits into the treatment landscape with Dr. Charles Turck as he takes a deep dive with Dr. Jamie Koprivnikar, MD, Hematologist, Oncologist, at Hackensack Meridian Health.
REBLOZYL® is a trademark of Celgene Corporation, a Bristol Myers Squibb company.
REBLOZYL® is licensed from Merck & Co. Inc., Rahway, NJ, USA and its affiliates.
© 2024 Bristol-Myers Squibb Company
2007-US-2300376 03/24
Host: Sana Raoof, MD, PhD
Guest: Candace T. Westgate, DO, MPH, FACOG
Guest: Mylynda Massart, MD, PhD
The last five years have seen exciting progress with liquid biopsy tests, with one of them being a screening tool for multi-cancer early detection that looks for methylation patterns that can detect more cancers earlier, even before symptoms appear.1,2 Learn how you can incorporate this screening tool into clinical practice with Drs. Sana Raoof, Candace Westgate, and Mylynda Massart. Dr. Raoof is a physician scientist at Memorial Sloan Kettering Cancer Center, Dr. Westgate is the Medical Director of the AHEAD Program and Chief of Staff at Adventist Health Saint Helena in Northern California, and Dr. Massart is the Founder and Director of the UPMC’s Primary Care Precision Medicine Center.
References:
- Nadauld LD, McDonnell CH 3rd, Beer TM, et al. The PATHFINDER Study: Assessment of the implementation of an investigational multi-cancer early detection test into clinical practice. Cancers (Basel). 2021;13(14):3501. Published 2021 Jul 13. doi:10.3390/cancers13143501
- Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV; CCGA Consortium. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31(6):745-759. doi:10.1016/j.annonc.2020.02.011
Host: Jennifer Caudle, DO
Guest: Sana Raoof, MD, PhD
There’s a multi-cancer early detection test available that uses a targeted methylation, next-generation sequencing-based assay to detect and analyze cell-free DNA in the bloodstream, deploy machine learning to detect a cancer signal, and predict the likely origin of the signal.2 Explore the science behind this advancement that provides the highest specificity of any cancer screening tool1 with Dr. Jennifer Caudle and Dr. Sana Raoof, physician scientist at Memorial Sloan Kettering Cancer Center.
References:
- Nadauld LD, McDonnell CH 3rd, Beer TM, et al. The PATHFINDER Study: Assessment of the implementation of an investigational multi-cancer early detection test into clinical practice. Cancers (Basel). 2021;13(14):3501. Published 2021 Jul 13. doi:10.3390/cancers13143501
- Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV; CCGA Consortium. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31(6):745-759. doi:10.1016/j.annonc.2020.02.011
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jerome Goldschmidt, MD
Despite the potential benefits of biosimilars, such as decreased costs for patients, healthcare systems, and payers,1,2 their uptake in U.S. clinical practice has lagged behind that of the E.U.2 That’s why Dr. Jerome Goldschmidt joins Dr. Charles Turck to address common misconceptions surrounding biosimilars and examine key points in their development, manufacturing, and approval process. Dr. Goldschmidt is a medical oncology specialist practicing at Blue Ridge Cancer Care, and he’s also affiliated with the U.S. Oncology Network in Blacksburg, Virginia.
References:
1. IQVIA. Biosimilars in the United States 2023–2027: Competition, Savings, and Sustainability. 2023. Accessed June 20, 2023. https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-the-united-states-2023-2027
2. Kvien TK, Patel K, Strand V. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum. 2022;52:151939. doi:10.1016/j.semarthrit.2021.11.009
©2023 Amgen Inc. All rights reserved. USA-CBU-81658 8/23
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Gil Melmed, MD, MS
The inflammation biosimilar development process uses a stepwise approach with increasing certainty to generate the totality of evidence, which demonstrates the safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed.1,2 Dive further into the role of totality of evidence in the inflammation biosimilar development and approval process with Dr. Gil Melmed, Director of Inflammatory Bowel Disease Clinical Research at the Cedars-Sinai and Professor of Medicine at Cedars-Sinai and at the David Geffen School of Medicine at University of California, Los Angeles. Dr. Melmed was compensated for participating in this program.
References:
-
US Food and Drug Administration. Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product Guidance for Industry. Published online April 2015. Accessed March 22, 2023. https://www.fda.gov/media/135612/download
-
US Food and Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product Guidance for Industry. Published online April 2015. Accessed March 22, 2023. https://www.fda.gov/media/82647/download
©2023 Amgen Inc. All rights reserved. USA-CBU-81605 5/23
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Eric Klein, MD
Cancer remains the second-leading cause of death in the U.S., creating an urgent need to detect cancer at earlier stages when outcomes are better. With the emergence of novel multi-cancer screening technologies, the potential public health impact may be substantial. Given these advances, is it time to rethink the way clinical trials are designed to assess the effectiveness of these screening technologies? Joining Dr. Charles Turck to discuss how we can utilize surrogate endpoints to evaluate the efficacy of cancer screening modalities is Dr. Eric Klein, a distinguished scientist at GRAIL.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Eric Klein, MD
While the state of cancer screening hasn’t seen too many changes over the years, the results from the PATHFINDER study may offer clinicians a new screening tool. Dr. Eric Klein from the Glickman Urological and Kidney Institute dives into this clinical data and how it might impact cancer screening protocols.
Host: Jennifer Caudle, DO
Guest: Majed Refaai, MD
While VKA-related GI bleeds are common, clinicians need to be aware of the severity of the bleed, especially in cases of hemodynamic instability. To get a better understanding of the impact of this severity, Dr. Majed Refaai from the University of Rochester Medical Center shares insights on these life-threatening bleeds.
Guest: Narjust Duma, MD
Guest: David J. Feller-Kopman, MD
Guest: Bruce E. Johnson, MD
Guest: Razelle Kurzrock, MD, FACP
Guest: Ignacio Wistuba, MD
Lung cancer incidence is decreasing due in part to reduced smoking rates, and new trends are emerging as things change. But despite these advancements, some challenges remain to be solved. Explore those challenges and key strategies for overcoming them in this four-part series.
PP-US-8201a-1520 12/22
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Clifford Takemoto, MD
With so many potential therapies emerging for sickle cell disease, where are we with the treatment of adults and children? Dr. Charles Turck joins Dr. Clifford Takemoto, the Chief of the Clinical Division of Hematology at St. Jude Children’s Research Hospital in Memphis, Tennessee, to share therapeutic updates from the 64th Annual American Society of Hematology Meeting.
HPV testing plays an important role in cervical cancer screening, but not every patient whose HPV-positive will develop cervical cancer. One option that can help us identify which HPV-positive patients are truly at risk is CINtec PLUS Cytology, an immunohistochemistry test that simultaneously detects p16 and Ki67 biomarker proteins. Learn more about how this dual staining technique works in this video.
Guest: Ilene Galinsky BSN,MSN,ANP-C
Here to review the ramp-up and dosing for venetoclax therapy in patients with newly diagnosed acute myeloid leukemia is Ilene Galinsky, Senior Program Research Nurse Practitioner for the Leukemia Program at Dana Farber Cancer Institute.
Guest: Lisa Nodzon PhD, ARNP, AOCNP
Both the disease itself and the treatments for chronic lymphocytic leukemia (CLL) can cause neutropenia, which is why Dr. Lisa Nodzon from the Moffitt Cancer Center is here to discuss neutropenia in relation to CLL treatment with venetoclax.
Guest: Lisa Nodzon PhD, ARNP, AOCNP
No matter whether you’re using venetoclax for chronic lymphocytic leukemia in the first-line or relapsed/refractory setting, there are some important considerations to keep in mind, like its dose ramp-up as well as the importance of hydration and tumor lysis syndrome prophylaxis. Tune in as Dr. Lisa Nodzon, advanced oncology certified nurse practitioner in the Department of Malignant Hematology at Moffitt Cancer Center, reviews those key considerations and more.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Harry Paul Erba, MD, PhD
Guest: Uma Borate, MD, MS
With the development of technologies paired with an enhanced understanding of the AML genomic landscape, it’s become possible to further the development of AML therapies. Joining Dr. Charles Turck to explore venetoclax and its role in current AML treatment paradigms are Drs. Uma Borate and Harry Erba.
Guest: Ilene Galinsky BSN,MSN,ANP-C
Patients with acute myeloid leukemia (AML) are at high risk for febrile neutropenia or profound, protracted neutropenia. So how can we monitor for the risk of neutropenia in AML patients starting venetoclax therapy? That’s what Ilene Galinsky, Senior Program Research Nurse Practitioner for the Leukemia Program at Dana Farber Cancer Institute, is here to explain.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Namrata Chandhok, MD
Underrepresentation is widespread in hematological clinical trials. To learn more about the challenges preventing representation—and possible solutions—Dr. Charles Turck joins Dr. Namrata Chandhok from the Sylvester Comprehensive Cancer Center at the University of Miami to share insights on inclusion in clinical trials from the American Society of Hematology annual Meeting.
Guest: Jeffery Andrews, MD, FRCSC
From the approval of an HPV test with extended genotyping to the role of the NCI Risk Matrix, what do we need to know about the ASCCP Risk-Based Management Consensus Guidelines, and how will these updates impact the treatment pathways we recommend to our patients being screening for cervical cancer? Dr. Jeffery Andrews shares guideline recommendations and updates.
HER2 (ERBB2) mutations may increase receptor internalization and lead to hyperactive downstream signaling, uncontrolled cell growth, and tumorigenesis. Learn more about how HER2 mutations affect several types of cancer, including non-small cell lung cancer (NSCLC).
Intended for US Healthcare Professions only
©2022 Daiichi Sankyo, Inc. and AstraZeneca. PP-US-8201a-1332 06/22
Guest: Joel Neal, MD, PhD
Guest: Alexander Spira, MD, PhD, FACP
With the recent approvals of mobocertinib and amivantamab, we now have targeted therapies for EGFR exon 20 insertion–positive locally advanced or metastatic NSCLC, following progression on or after platinum-based chemotherapy. To learn more about mobocertinib, Dr. Joel Neal (Stanford) speaks with Dr. Alexander Spira (Virginia Cancer Specialists Research Institute) about the historical unmet need for this patient population, how mobocertinib is different from classical EGFR TKIs, and the clinical data that led to its FDA approval.
All trademarks are property of their respective owners.
Guest: S. Michelle Shiller, DO, AP/CP, MGP
Guest: John V. Heymach, MD, PhD
Exon 20 insertion mutations account for up to 10 percent of EGFR mutations and approximately 2 percent of all non-small cell lung cancer mutations. Although less common, EGFR mutations at exon 20 have an important impact on therapy selection. That’s why Dr. John Heymach speaks with Dr. Michelle Shiller about what those impacts are as well as the available therapies for patients with these mutations.
All trademarks are the property of their respective owners.
Guest: Azra Raza, MD
Guest: Rami Komrokji, MD
Listen to hematologist-oncologists Drs. Rami Komrokji and Azra Raza discuss myelodysplastic syndromes (MDS). Together, they explain the classification system for diagnosing this rare blood disorder and touch upon current events in the space and the impact on patients living with MDS.
© TAIHO ONCOLOGY 11/2021 INQ-PM-US-0384
Guest: Rami Komrokji, MD
Guest: Natasha Johnson, MSN, APRN, AOCNP
Myelodysplastic syndromes (MDS) can require lifelong treatment.1 Learn how hematologist-oncologist Dr. Rami Komrokji and nurse practitioner Ms. Natasha Johnson approach their MDS protocol–from characterization, to diagnosis, to treatment. Together, they explain their process for scoring, transplants, and choosing a treatment regimen. They also share their experiences with INQOVI® (decitabine and cedazuridine), the only oral hypomethylating agent in the treatment of MDS, including chronic myelomonocytic leukemia.2
References: 1. Platzbecker U. Treatment of MDS. Blood. 2019;133(10):1096-1107. 2. INQOVI [package insert]. Princeton, NJ: Taiho Oncology, Inc.; 2022.
Guest: Ashley Moncrief, RN, BSN
Guest: Natasha Johnson, MSN, APRN, AOCNP
Tune in to hear nurse practitioners Ms. Natasha Johnson and Ms. Ashley Moncrief discuss myelodysplastic syndromes (MDS), a rare type of blood cancer, and how it is classified and identified. Together, they share personal experiences from their practices and tips for conversations with MDS patients about their care.
© TAIHO ONCOLOGY 11/2021 INQ-PM-US-0390
Host: Jennifer Caudle, DO
Guest: Mark Socinski, MD
Dr. Mark Socinski from the AdventHealth Cancer Institute in Florida joins Dr. Jennifer Caudle to discuss a patient profile in the treatment of relapsed small cell lung cancer to help us better understand the burden of this disease and how to approach treating patients in the second-line setting with treatment options like ZEPZELCA.
Have you considered POMALYST® (pomalidomide) containing regimens for your appropriate patients with relapsed/refractory multiple myeloma who have received lenalidomide and a proteasome inhibitor? Tune in to hear key findings from clinical trials, including safety and efficacy data, and other important information regarding these treatment regimens.
Please see full Prescribing Information for POMALYST, including Boxed WARNINGS, and full Prescribing Information for EMPLICITI.
POMALYST and EMPLICITI Indications
POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
EMPLICITI® (elotuzumab) is indicated in combination with POMALYST and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
POMALYST + dexamethasone + daratumumab Indication
POMALYST + dexamethasone + daratumumab is indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
Information about POMALYST + dexamethasone + …
Host: Jennifer Caudle, DO
Guest: Keith McCrae, MD
In order to reflect the evolving management of immune thrombocytopenia (ITP), the American Society of Hematology updated their clinical practice guidelines. Here to share some of the key recommendations for the management of adult and pediatric ITP is Dr. Keith McCrae, a board-certified hematologist and an author of the 2019 ASH Guidelines.
© 2021 Amgen Inc. All rights reserved. USA-531-80829 08/21
Host: Tracey Evans, MD
Guest: Raja Mudad, MD
For thirty years, there were limited therapeutic advancements leading to FDA approvals in extensive-stage small cell lung cancer (ES-SCLC). However, this all changed with the IMpower133 trial, which led to the emergence of immunotherapy as a first line treatment option in ES-SCLC. Joining Dr. Tracey Evans is medical oncologist Dr. Raja Mudad to discuss the IMpower133 trial and the reasons to consider TECENTRIQ® (atezolizumab), the first immunotherapy combination for patients with ES-SCLC.
This program is intended for US Physicians.
M-US-00010808(v1.0)
Host: Tracey Evans, MD
Guest: Raja Mudad, MD
TECENTRIQ® (atezolizumab), in combination with carboplatin and etoposide, is a first-line treatment option for adult patients with extensive-stage small cell lung cancer. What does this treatment path look like in clinical practice? Dr. Tracey Evans is joined by medical oncologist Dr. Raja Mudad to walk us through an example patient case that gives us a better sense of key diagnostic factors, treatment approach, and patient management.
This program is intended for US Physicians.
M-US-00010814(v1.0)
Host: Jennifer Caudle, DO
Guest: Tracey Evans, MD
Small cell lung cancer (SCLC) is a highly aggressive, lethal, and widely metastatic lung cancer. While therapeutic progress in SCLC has been limited over the years, immunotherapy has made some meaningful advancements in the treatment landscape. Joining Dr. Jennifer Caudle to discuss key diagnostic and therapeutic considerations such as TECENTRIQ® (atezolizumab) for 1L ES-SCLC, is Dr. Tracey Evans, Director of Thoracic Oncology Research at Lankenau Institute for Medical Research and Co-Director of the Thoracic Oncology Program at Main Line Health.
This program is intended for US Physicians.
M-US-00010802(v1.0)
Host: Joel Wedd MD, MPH
Not only is hepatocellular carcinoma (HCC) the most common primary liver cancer in adults, but it’s also the fastest-growing cause of cancer-related deaths in the US. That’s why Dr. Joel Wedd, Associate Professor of Medicine at the Virginia Commonwealth University and Medical Director of Liver Transplant at the Hume-Lee Transplant Center, is here to discuss the pathogenesis of hepatocellular carcinoma, risk factors, the importance of early-stage detection, and more.
Guest: Andy Arwari, MD
With more patients opting for home-based care over long-term, acute, and office-based care, it’s important that we align with our patients on what’s most important to them and how they want to be cared for, especially those who are nearing the end of life.
That’s why VITAS Medical Director, Dr. Andy Arwari, is here to share the purpose of goals-of-care conversations and how an app can aid in determining if an advanced illness patient is eligible for hospice.
Host: Matt Birnholz, MD
Guest: Christopher P. Evans, M.D., F.A.C.S.
Guest: Maha Hussain, MD, FACP, FASCO
Prostate cancer is one of the most common cancers in men in the United States. In a program sponsored by Astellas and Pfizer, Drs. Maha Hussain and Christopher Evans discuss the history and how care is evolving for men with metastatic prostate cancer and non-metastatic castration-resistant prostate cancer.
This program is intended for United States health care professionals only. Drs. Hussain and Evans have recevied compensation from Astellas and Pfizer for their time.
074-0391-PM
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Nicole Lamanna, MD
The anti-apoptotic protein B-cell lymphoma 2 (BCL2) is a key regulator of the intrinsic apoptotic pathway and is often overexpressed in chronic lymphocytic leukemia (CLL) cells. That’s why BCL2 represents an important therapeutic target for CLL, and joining Dr. Charles Turck to look at Venetoclax, a treatment option that targets this protein is Dr. Nicole Lamanna, an Associate Clinical Professor of Medicine at Columbia University Medical Center in New York.
Host: Jennifer Caudle, DO
Guest: Coy Heldermon, MD, PhD
Guest: Heather Lau, MD, MS
Several questions are often brought to light when it comes to detecting and diagnosing Gaucher disease, such as how does it present, what genetic factors to consider, and how to go about making an accurate diagnosis. Here to answer those and other questions are practicing hematologist oncologist Dr. Coy Heldermon and neurogeneticist Dr. Heather Lau.
For more information on the diagnostic and therapeutic landscape for Gaucher disease, including access to Sanofi Genzyme Rare Disease Registries, visit Gauchercare.com/hcp, a Sanofi Genzyme website.
MAT-US-2024074 2/2021
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Harry Paul Erba, MD, PhD
Guest: Uma Borate, MD, MS
With the development of technologies paired with an enhanced understandings of the AML genomic landscape, it’s become possible to develop targeted AML therapies. Joining Dr. Charles Turck to explore Venetoclax and its role in current AML treatment paradigms are Drs. Uma Borate and Harry Erba.
Host: Jennifer Caudle, DO
Guest: Tracey Evans, MD
Join Dr. Tracey Evans as she discusses the efficacy data for TAGRISSO® (osimertinib) and the potential impact for metastatic EGFRm NSCLC patients.
In 2018, first-line TAGRISSO became a standard of care for metastatic EGFRm NSCLC with an unprecedented 18.9 months median PFS vs 10.2 months for erlotinib/gefitinib (HR=0.46 [95% CI: 0.37, 0.57]; P<0.0001).1
Now, TAGRISSO is the only EGFR TKI to deliver statistically significant Overall Survival beyond 3 years in a global, phase 3 randomized clinical trial in the first-line setting, (38.6 months vs 31.8 months for erlotinib/gefitinib (HR=0.799 [95.05% CI: 0.641, 0.997]; P=0.0462)).2
Visit TagrissoHCP.com to learn what these data could mean for your patients.
FLAURA study design: Randomized, double-blind, active-controlled trial in 556 patients with metastatic EGFRm NSCLC who had not received prior systemic treatment for advanced disease. Patients were randomized 1:1 to either TAGRISSO (n=279; 80 mg orally, once daily) or EGFR-TKI comparator (n=277; gefitinib 250 mg or erlotinib 150 mg orally, once daily). All US patients in the comparator arm received erlotinib. Crossover was allowed for patients in the EGFR-TKI comparator arm at confirmed progression if positive for the EGFR T790M resistance mutation. Patients with CNS metastases not requiring …
Guest: Jason Day
Guest: Dening Day
Biomarker testing is a critical step in any mNSCLC patient’s treatment journey, as PGA champion Jason Day found out when his mother, Dening, was diagnosed with the disease.1-3
In this video, Jason and Dening tell their story about how biomarker testing helped Dening get on a therapy that can target the driver of her disease. Jason and Dening’s story may help your newly diagnosed mNSCLC patients understand the importance of testing their lung cancer, knowing the full molecular results, and treating based on those results.
Share this video and more with your patients by visiting TestLungCancer.com.
References:
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCLC V.3.2020. ©National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed February 11, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
- Brahmer JR, Govindan R, Anders RA, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J …